Issues

Existing pharmaceutical business models are likely to change dramatically over the next decade in response to global industry trends.

The move towards personalised medicine at a time of unprecedented pressure on healthcare budgets will lead to greater focus on payment for managed outcomes, less tolerance for "me too" drugs.

At the same time, falling R&D productivity and a greater move to manufacturing outsourcing means that pharmaceutical companies supply chains are likely to become more complex and to have more associated parties than at present.

In this new environment, how are you planning to alter your business model to protect your existing operations and to take advantage of the new opportunities that will undoubtedly arise?

As leading advisor to the sector both in Ireland and internationally, our understanding of these challenges and their potential impact is unrivalled. Whether it is planning ahead or planning to stay ahead, we can help.